Company profile
Versantis AG
Versantis is a global, clinical-stage pharmaceutical company addressing the growing, un-met medical need in liver diseases. Our lead program VS-01 leverages our proprietary scavenging liposomes technology to timely reverse the multi-organ complications arising from liver cirrhosis. It was shown to be safe and well tolerated in a Ph1b study with positive efficacy outcomes, and is now ready to start Phase 2a clinical investigations. VS-01 was granted orphan drug designations by the FDA and EMA, which help streamlining its clinical development pathway.
Source: startup.ch
Highlights
Top 100 Swiss Startup Award 2020
Top 100 Swiss Startup Award 2019
Top 100 Swiss Startup Award 2018
Top 100 Swiss Startup Award 2017
Top 100 Swiss Startup Award 2016
Top 100 Swiss Startup Award 2015
Winner Venture Kick
Innosuisse Certificate
